Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Roger Owen

Showing results (21-30 of 71) with videos related to

Pageof 8
Sort By:
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|November 20, 2012
Correlation of in vitro lymphocyte radiosensitivity and gene expression with late normal tissue reactions following curative radiotherapy for breast cancerPaul Finnon, Sylwia Kabacik, Alan MacKay, et al.
Pulmonary Pharmacology & Therapeutics|July 13, 2010
Sustained 24-hour efficacy of once daily indacaterol (300 μg) in patients with chronic obstructive pulmonary disease: a randomized, crossover studyCraig Laforce, Joseph Aumann, Luis de Teresa Parreño, et al.
Cancer Genetics and Cytogenetics|January 22, 2004
Rapid diagnosis of acute promyelocytic leukemia (PML): applicability of flow cytometry and PML protein immunofluorescenceMatthew J Cullen, Stephen J Richards, Sheila J M O'Connor, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|May 10, 2005
TGFB1 polymorphisms are associated with risk of late normal tissue complications in the breast after radiotherapy for early breast cancerChristian Nicolaj Andreassen, Jan Alsner, Jens Overgaard, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|May 16, 2012
Efficacy of once-daily indacaterol relative to alternative bronchodilators in COPD: a patient-level mixed treatment comparisonShannon Cope, Gorana Capkun-Niggli, Rupert Gale, et al.
Thorax|June 5, 2010
Efficacy of a new once-daily long-acting inhaled beta2-agonist indacaterol versus twice-daily formoterol in COPDRonald Dahl, Kian Fan Chung, Roland Buhl, et al.
British Journal of Haematology|January 12, 2022
Diagnosis and management of Waldenström macroglobulinaemia-A British Society for Haematology guidelineGuy Pratt, Dima El-Sharkawi, Jaimal Kothari, et al.
Respiratory Medicine|May 16, 2008
A dose-ranging study of indacaterol in obstructive airways disease, with a tiotropium comparisonStephen Rennard, Theo Bantje, Stefano Centanni, et al.
The Lancet. Oncology|June 6, 2006
Effect of radiotherapy fraction size on tumour control in patients with early-stage breast cancer after local tumour excision: long-term results of a randomised trialJ Roger Owen, Anita Ashton, Judith M Bliss, et al.
Frontiers in Immunology|January 11, 2021
Evidence of B Cell Clonality and Investigation Into Properties of the IgM in Patients With Schnitzler SyndromeShelly Pathak, Dorota Rowczenio, Samuel Lara-Reyna, et al.
Pageof 8

Showing results (21-30 of 71) with videos related to

Sort By:
Pageof 8
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|November 20, 2012
Correlation of in vitro lymphocyte radiosensitivity and gene expression with late normal tissue reactions following curative radiotherapy for breast cancerPaul Finnon, Sylwia Kabacik, Alan MacKay, et al.
Pulmonary Pharmacology & Therapeutics|July 13, 2010
Sustained 24-hour efficacy of once daily indacaterol (300 μg) in patients with chronic obstructive pulmonary disease: a randomized, crossover studyCraig Laforce, Joseph Aumann, Luis de Teresa Parreño, et al.
Cancer Genetics and Cytogenetics|January 22, 2004
Rapid diagnosis of acute promyelocytic leukemia (PML): applicability of flow cytometry and PML protein immunofluorescenceMatthew J Cullen, Stephen J Richards, Sheila J M O'Connor, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|May 10, 2005
TGFB1 polymorphisms are associated with risk of late normal tissue complications in the breast after radiotherapy for early breast cancerChristian Nicolaj Andreassen, Jan Alsner, Jens Overgaard, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|May 16, 2012
Efficacy of once-daily indacaterol relative to alternative bronchodilators in COPD: a patient-level mixed treatment comparisonShannon Cope, Gorana Capkun-Niggli, Rupert Gale, et al.
Thorax|June 5, 2010
Efficacy of a new once-daily long-acting inhaled beta2-agonist indacaterol versus twice-daily formoterol in COPDRonald Dahl, Kian Fan Chung, Roland Buhl, et al.
British Journal of Haematology|January 12, 2022
Diagnosis and management of Waldenström macroglobulinaemia-A British Society for Haematology guidelineGuy Pratt, Dima El-Sharkawi, Jaimal Kothari, et al.
Respiratory Medicine|May 16, 2008
A dose-ranging study of indacaterol in obstructive airways disease, with a tiotropium comparisonStephen Rennard, Theo Bantje, Stefano Centanni, et al.
The Lancet. Oncology|June 6, 2006
Effect of radiotherapy fraction size on tumour control in patients with early-stage breast cancer after local tumour excision: long-term results of a randomised trialJ Roger Owen, Anita Ashton, Judith M Bliss, et al.
Frontiers in Immunology|January 11, 2021
Evidence of B Cell Clonality and Investigation Into Properties of the IgM in Patients With Schnitzler SyndromeShelly Pathak, Dorota Rowczenio, Samuel Lara-Reyna, et al.
Pageof 8